Biogen BIIB reported first-quarter 2025 adjusted earnings per share (EPS) of $3.02, which missed the Zacks Consensus Estimate ...

Biotech company Biogen (NASDAQ:BIIB) reported Q1 CY2025 results , with sales up 6.1% year on year to $2.43 billion. Its ...

The drugmaker posted Q1 adjusted earnings per share (EPS) of $3.02, topping the $2.96 consensus. Revenue for the period climbed 6% year-over-year to $2.43 billion, also above the $2.23 billion average ...

Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to ...

Biogen’s lack of insider buying and reduced R&D spending raise concerns, but its future growth prospects remain. Find out why ...

Keeping that in mind, here is one low-volatility stock that could succeed under all market conditions and two stuck in limbo.

Analysts fell to the sidelines weighing in on Biogen (BIIB – Research Report) and Sanofi (SNY – Research Report) with neutral ratings, ...

In a report released yesterday, Salveen Richter from Goldman Sachs maintained a Buy rating on Biogen (BIIB – Research Report), with a price ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the ...

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Biogen (BIIB – Research Report), with a price target ...

Shares of BIIB stock opened at $118.61 on Wednesday. The company’s fifty day simple moving average is $134.29 and its two-hundred day simple moving average is $151.69. Biogen has a 52 week low ...

Biogen Inc. (NASDAQ:BIIB – Free Report) – Leerink Partnrs cut their Q1 2025 earnings estimates for Biogen in a research report issued on Sunday, April 13th. Leerink Partnrs analyst M.